title: Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
abstract: OBJECTIVE
  The peptide vaccine candidates identified to date have been focused on the HLA-A2 and HLA-A24 alleles. The HLA-A11, HLA-A31, and HLA-A33 alleles share binding motifs and belong to an HLA-A3 supertype family. In this study, we attempted to identify CTL-directed peptide candidates, derived from prostate-related antigens and shared by HLA-A11+, HLA-A31+, and HLA-A33+ prostate cancer patients.
  
  
  METHODS
  Based on the binding motif to the HLA-A3 supertype alleles, 42 peptides were prepared from prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), and prostatic acid phosphatase (PAP). These peptides were first screened for their ability to be recognized by immunoglobulin G (IgG) of prostate cancer patients and subsequently for the potential to induce peptide-specific and prostate cancer-reactive CTLs from peripheral blood mononuclear cells (PBMC) of cancer patients with the HLA-A11, HLA-A31, and HLA-A33 alleles.
  
  
  RESULTS
  Five peptide candidates, including the PSA(16-24), PAP(155-163), PAP(248-257), PSMA(207-215), and PSMA(431-440) peptides, were frequently recognized by IgGs of prostate cancer patients. These peptides efficiently induced peptide-specific and prostate cancer-reactive CTLs from PBMCs of cancer patients with the HLA-A11, HLA-A31, and HLA-A33 alleles. Antibody blocking and cold inhibition experiments revealed that the HLA-A3 supertype-restricted cytotoxicity against prostate cancer cells could be ascribed to peptide-specific and CD8+ T cells.
  
  
  CONCLUSIONS
  We identified prostate-related antigen-derived new peptide candidates for HLA-A11-, HLA-A31-, and HLA-A33-positive prostate cancer patients. This information could facilitate the development of a peptide-based anticancer vaccine for patients with alleles other than HLA-A2 and HLA-A24.
authors.affiliation: Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
authors.forename: Satoko
authors.initials: S
authors.lastname: Matsueda
authors.forename: Hiroko
authors.initials: H
authors.lastname: Takedatsu
authors.forename: Akihisa
authors.initials: A
authors.lastname: Yao
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tanaka
authors.forename: Masanori
authors.initials: M
authors.lastname: Noguchi
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
authors.forename: Mamoru
authors.initials: M
authors.lastname: Harada
mesh_terms: D000135:Acid Phosphatase; D000483:Alleles; D020816:Amino Acid Motifs; D000954:Antigens, Surface / Q000096:biosynthesis; D019496:Cancer Vaccines; D045744:Cell Line, Tumor; D003080:Cold Temperature; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry; D043425:Glutamate Carboxypeptidase II / Q000096:biosynthesis; D015234:HLA-A Antigens / Q000737:chemistry; D059870:HLA-A11 Antigen; D015791:HLA-A3 Antigen / Q000096:biosynthesis / Q000737:chemistry*; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry; D007963:Leukocytes, Mononuclear / Q000166:cytology; D008297:Male; D010455:Peptides / Q000737:chemistry*; D017430:Prostate-Specific Antigen / Q000096:biosynthesis; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D017434:Protein Structure, Tertiary; D017027:Protein Tyrosine Phosphatases / Q000096:biosynthesis; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology
chemical_list: D000954:Antigens, Surface; D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D015234:HLA-A Antigens; C082945:HLA-A*33 antigen; D059870:HLA-A11 Antigen; D015791:HLA-A3 Antigen; C069527:HLA-A31 antigen; D007074:Immunoglobulin G; D010455:Peptides; D000135:Acid Phosphatase; C428439:prostatic acid phosphatase; D017027:Protein Tyrosine Phosphatases; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D017430:Prostate-Specific Antigen